Skip to main content
Top
Published in: Molecular Cancer 1/2009

Open Access 01-12-2009 | Research

Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway

Authors: Peixin Dong, Zhujie Xu, Nan Jia, Dajin Li, Youji Feng

Published in: Molecular Cancer | Issue 1/2009

Login to get access

Abstract

Background

p53 is the most commonly mutated tumor suppressor gene in human cancers. In addition to the loss of tumor suppression function and exertion of dominant-negative effects over the remaining wild-type protein, several p53 mutants can gain novel oncogenic functions (gain-of-function, GOF) that actively regulate cancer development and progression. In human endometrial cancer, p53 mutation is more often associated with aggressive nonendometrioid cancer. However, it was unknown if p53 mutants contributed to endometrial cancer progression through the GOF properties.

Methods

To clarify the relationship between expression of p53 GOF mutation (p53-R175H) and invasive potential of human endometrial cancer KLE cells, we tested the consequences of up-regulation and down-regulation of p53-R175H in KLE cells by inducing p53-R175H expression vector or suppressing the p53 gene with short hairpin RNA.

Results

We found that forced over-expression of p53-R175H significantly promoted cell migration and invasion, and induced activation of the epidermal growth factor receptor (EGFR)/phosphatidylinositol 3-kinase (PI3K)/AKT pathway. Conversely, suppression of p53-R175H with short hairpin RNA significantly inhibited cell migration and invasion, and resulted in attenuation of EGFR/PI3K/AKT pathway.

Conclusion

These findings show for the first time that elevated expression of p53-R175H mutant may exert gain-of-function activity to activate the EGFR/PI3K/AKT pathway and thus may contribute to the invasive phenotype in endometrial cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin. 2005, 55: 10-30. 10.3322/canjclin.55.1.10CrossRefPubMed Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ: Cancer statistics, 2005. CA Cancer J Clin. 2005, 55: 10-30. 10.3322/canjclin.55.1.10CrossRefPubMed
2.
go back to reference Parazzini F, Lavecchia C, Bocciolone L, Franceschi S: The epidemiology of endometrial cancer. Gynecol Oncol. 1998, 41: 1-16. 10.1016/0090-8258(91)90246-2. 10.1016/0090-8258(91)90246-2CrossRef Parazzini F, Lavecchia C, Bocciolone L, Franceschi S: The epidemiology of endometrial cancer. Gynecol Oncol. 1998, 41: 1-16. 10.1016/0090-8258(91)90246-2. 10.1016/0090-8258(91)90246-2CrossRef
3.
go back to reference Sakuragi N, Hirai A, Tada M, Yamada H, Yamamoto R, Fujimoto S, Moriuchi T: Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma. Gynecol Oncol. 2001, 83: 485-490. 10.1006/gyno.2001.6429CrossRefPubMed Sakuragi N, Hirai A, Tada M, Yamada H, Yamamoto R, Fujimoto S, Moriuchi T: Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma. Gynecol Oncol. 2001, 83: 485-490. 10.1006/gyno.2001.6429CrossRefPubMed
4.
go back to reference Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene. 2005, 24: 2899-2908. 10.1038/sj.onc.1208615CrossRefPubMed Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene. 2005, 24: 2899-2908. 10.1038/sj.onc.1208615CrossRefPubMed
5.
go back to reference Willis A, Jung EJ, Wakefield T, Chen X: Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene. 2004, 23: 2330-2338. 10.1038/sj.onc.1207396CrossRefPubMed Willis A, Jung EJ, Wakefield T, Chen X: Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene. 2004, 23: 2330-2338. 10.1038/sj.onc.1207396CrossRefPubMed
6.
go back to reference Dong P, Tada M, Hamada J, Nakamura A, Moriuchi T, Sakuragi N: p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. Clin Exp Metastasis. 2007, 24: 471-483. 10.1007/s10585-007-9084-8CrossRefPubMed Dong P, Tada M, Hamada J, Nakamura A, Moriuchi T, Sakuragi N: p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells. Clin Exp Metastasis. 2007, 24: 471-483. 10.1007/s10585-007-9084-8CrossRefPubMed
7.
go back to reference Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996, 2: 811-814. 10.1038/nm0796-811CrossRefPubMed Aas T, Børresen AL, Geisler S, Smith-Sørensen B, Johnsen H, Varhaug JE, Akslen LA, Lønning PE: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996, 2: 811-814. 10.1038/nm0796-811CrossRefPubMed
8.
go back to reference Wang XJ, Greenhalgh DA, Jiang A, He D, Zhong L, Brinkley BR, Roop DR: Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function. Mol Carcinog. 1998, 23: 185-192. 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5CrossRefPubMed Wang XJ, Greenhalgh DA, Jiang A, He D, Zhong L, Brinkley BR, Roop DR: Analysis of centrosome abnormalities and angiogenesis in epidermal-targeted p53172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function. Mol Carcinog. 1998, 23: 185-192. 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5CrossRefPubMed
9.
go back to reference Müller BF, Paulsen D, Deppert W: Specific binding of MAR/SAR DNA-elements by mutant p53. Oncogene. 1996, 12: 1941-1952.PubMed Müller BF, Paulsen D, Deppert W: Specific binding of MAR/SAR DNA-elements by mutant p53. Oncogene. 1996, 12: 1941-1952.PubMed
10.
go back to reference Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, Haas M: Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol. 1994, 145: 702-714.PubMedCentralPubMed Hsiao M, Low J, Dorn E, Ku D, Pattengale P, Yeargin J, Haas M: Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol. 1994, 145: 702-714.PubMedCentralPubMed
11.
go back to reference Blandino G, Levine AJ, Oren M: Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999, 18: 477-485. 10.1038/sj.onc.1202314CrossRefPubMed Blandino G, Levine AJ, Oren M: Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999, 18: 477-485. 10.1038/sj.onc.1202314CrossRefPubMed
12.
go back to reference Bansal N, Yendluri V, Wenham RM: The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009, 16: 8-13.PubMed Bansal N, Yendluri V, Wenham RM: The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009, 16: 8-13.PubMed
13.
go back to reference Yaginuma Y, Westphal H: Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res. 1991, 51: 6506-6509.PubMed Yaginuma Y, Westphal H: Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res. 1991, 51: 6506-6509.PubMed
14.
go back to reference Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002, 296: 550-553. 10.1126/science.1068999CrossRefPubMed Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002, 296: 550-553. 10.1126/science.1068999CrossRefPubMed
15.
go back to reference Oleinik NV, Krupenko NI, Priest DG, Krupenko SA: Cancer cells activate p53 in response to 10-formyltetrahydrofolate dehydrogenase expression. Biochem J. 2005, 391: 503-511. 10.1042/BJ20050533PubMedCentralCrossRefPubMed Oleinik NV, Krupenko NI, Priest DG, Krupenko SA: Cancer cells activate p53 in response to 10-formyltetrahydrofolate dehydrogenase expression. Biochem J. 2005, 391: 503-511. 10.1042/BJ20050533PubMedCentralCrossRefPubMed
16.
go back to reference Hamada Ji, Omatsu T, Okada F, Furuuchi K, Okubo Y, Takahashi Y, Tada M, Miyazaki YJ, Taniguchi Y, Shirato H, Miyasaka K, Moriuchi T: Overexpression of homeobox gene HOXD3 induces coordinate expression of metastasis-related genes in human lung cancer cells. Int J Cancer. 2001, 93: 516-525. 10.1002/ijc.1357CrossRef Hamada Ji, Omatsu T, Okada F, Furuuchi K, Okubo Y, Takahashi Y, Tada M, Miyazaki YJ, Taniguchi Y, Shirato H, Miyasaka K, Moriuchi T: Overexpression of homeobox gene HOXD3 induces coordinate expression of metastasis-related genes in human lung cancer cells. Int J Cancer. 2001, 93: 516-525. 10.1002/ijc.1357CrossRef
17.
go back to reference Fujita H, Okada F, Hamada J, Hosokawa M, Moriuchi T, Koya RC, Kuzumaki N: Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer. 2001, 93: 773-780. 10.1002/ijc.1413CrossRefPubMed Fujita H, Okada F, Hamada J, Hosokawa M, Moriuchi T, Koya RC, Kuzumaki N: Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer. 2001, 93: 773-780. 10.1002/ijc.1413CrossRefPubMed
18.
go back to reference Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor - positive tumors. A new paradigm for cancer therapy. American Cancer Society. 2002, 94: 1593-1611. Herbst RS, Shin DM: Monoclonal antibodies to target epidermal growth factor receptor - positive tumors. A new paradigm for cancer therapy. American Cancer Society. 2002, 94: 1593-1611.
19.
go back to reference Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006, 366: 2-16. 10.1016/j.gene.2005.10.018CrossRefPubMed Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006, 366: 2-16. 10.1016/j.gene.2005.10.018CrossRefPubMed
20.
go back to reference Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW: Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994, 53: 84-92. 10.1006/gyno.1994.1092CrossRefPubMed Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW: Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994, 53: 84-92. 10.1006/gyno.1994.1092CrossRefPubMed
21.
go back to reference Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE, Brown DR, Deb SP, Deb S: Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol. 1996, 16: 6009-6019.PubMedCentralPubMed Ludes-Meyers JH, Subler MA, Shivakumar CV, Munoz RM, Jiang P, Bigger JE, Brown DR, Deb SP, Deb S: Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol. 1996, 16: 6009-6019.PubMedCentralPubMed
22.
go back to reference Lee DH, Szczepanski MJ, Lee YJ: Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem. 2009, 106: 1113-1122. 10.1002/jcb.22098CrossRefPubMed Lee DH, Szczepanski MJ, Lee YJ: Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J Cell Biochem. 2009, 106: 1113-1122. 10.1002/jcb.22098CrossRefPubMed
23.
go back to reference Zhou C, Qiu L, Sun Y, Healey S, Wanebo H, Kouttab N, Di W, Yan B, Wan Y: Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int J Oncol. 2006, 29: 269-278.PubMed Zhou C, Qiu L, Sun Y, Healey S, Wanebo H, Kouttab N, Di W, Yan B, Wan Y: Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int J Oncol. 2006, 29: 269-278.PubMed
24.
go back to reference Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A: Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene. 2006, 25: 304-309.PubMed Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A: Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene. 2006, 25: 304-309.PubMed
25.
go back to reference Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ: Gain of function mutations in p53. Nat Genet. 1993, 4: 42-46. 10.1038/ng0593-42CrossRefPubMed Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ: Gain of function mutations in p53. Nat Genet. 1993, 4: 42-46. 10.1038/ng0593-42CrossRefPubMed
26.
go back to reference Jones MW, Kounelis S, Hsu C, Papadaki H, Bakker A, Swalsky PA, Finkelstein SD: Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison. Int J Gynecol Pathol. 1997, 16: 354-360. 10.1097/00004347-199710000-00010CrossRefPubMed Jones MW, Kounelis S, Hsu C, Papadaki H, Bakker A, Swalsky PA, Finkelstein SD: Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison. Int J Gynecol Pathol. 1997, 16: 354-360. 10.1097/00004347-199710000-00010CrossRefPubMed
27.
go back to reference Hsiao M, Low J, Dorn E, Ku D, Pattenganle P, Yeargin J, Haas M: Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol. 1994, 145: 702-714.PubMedCentralPubMed Hsiao M, Low J, Dorn E, Ku D, Pattenganle P, Yeargin J, Haas M: Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol. 1994, 145: 702-714.PubMedCentralPubMed
28.
go back to reference Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer. 2001, 37: 9-15. 10.1016/S0959-8049(01)00231-3CrossRef Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer. 2001, 37: 9-15. 10.1016/S0959-8049(01)00231-3CrossRef
29.
go back to reference Khalifa MA, Abdoh AA, Mannel RS, Haraway SD, Walker JL, Min KW: Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer. 1994, 73: 370-376. 10.1002/1097-0142(19940115)73:2<370::AID-CNCR2820730222>3.0.CO;2-NCrossRefPubMed Khalifa MA, Abdoh AA, Mannel RS, Haraway SD, Walker JL, Min KW: Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer. 1994, 73: 370-376. 10.1002/1097-0142(19940115)73:2<370::AID-CNCR2820730222>3.0.CO;2-NCrossRefPubMed
30.
go back to reference Lipponen P, Eskelinen M: Expression of epidermal growth factor receptor in bladder cancer as related to mutant p53 expression and long-term prognosis. Br J Cancer. 1994, 69: 1120-1125.PubMedCentralCrossRefPubMed Lipponen P, Eskelinen M: Expression of epidermal growth factor receptor in bladder cancer as related to mutant p53 expression and long-term prognosis. Br J Cancer. 1994, 69: 1120-1125.PubMedCentralCrossRefPubMed
31.
go back to reference Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2: 127-137. 10.1038/35052073CrossRefPubMed Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2: 127-137. 10.1038/35052073CrossRefPubMed
Metadata
Title
Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway
Authors
Peixin Dong
Zhujie Xu
Nan Jia
Dajin Li
Youji Feng
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2009
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-8-103

Other articles of this Issue 1/2009

Molecular Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine